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Abstract 
 
Aims: No recommendations currently exist regarding implementation of 
both prenatal diagnosis and preimplantation genetic diagnosis (PGD) for 
Autosomal Dominant Polycystic Kidney Disease (ADPKD). This study 
evaluated attitudes in ADPKD patients with either chronic kidney disease (CKD) 
stages I-IV or end stage renal failure (ESRF) towards prenatal diagnosis and PGD.  
 
Methods: 96 ADPKD patients were recruited from an outpatient clinic, wards 
and dialysis units. 38 patients had end stage renal failure (ESRF) and 58 had 
chronic kidney disease (CKD) stages I-IV. Participants were given an information 
sheet on prenatal diagnosis and PGD and subsequently completed a 
questionnaire.  
 
Results: The median age of participants was 51.5 years. 17% ADPKD patients 
with CKD and 18% ADPKD patients with ESRF would consider prenatal 
diagnosis and termination of pregnancy for ADPKD. 50% with CKD would have 
opted for PGD (or might consider it in the future) were it available and funded by 
the  UK National Health Service, compared to 63% in the ESRF group (p = 0.33). 
69% in the CKD group and 68% in the ESRF group believed that PGD should be 
offered to other patients.  
 
Discussion: There was a spectrum of attitudes amongst this cohort. A  
proportion of patients believe that PGD should be made available to prospective 
parents with this disease. The discrepancy between the low proportion (17% 
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CKD, 18% ESRF) who would consider prenatal diagnosis and termination of 
pregnancy and the higher number who hypothetically express an intention or 
wish to access PGD (50% CKD and 63% ESRF) indicate far greater acceptability 
for diagnostic methods that occur before embryo implantation. It is not known 
how the development of methods to identify patients whose renal function is 
likely to decline rapidly and treatments altering the natural history of ADPKD 
will affect these attitudes. 
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Introduction 
 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most prevalent 
potentially lethal monogenic disorder (Torres et al., 2007).  Recent estimates 
have put the overall prevalence of ADPKD at 32.7 per 100000 with a maximum 
prevalence of 57.3 per 100000 in the 6th decade of life (Neumann et al., 2013). 7 
to 10% of patients receiving haemodialysis have ADPKD. Extrarenal 
manifestations of the disease include liver cysts, cardiac valve abnormalities and 
aortic and intracranial aneurysms  (Wilson, 2004). 
 
Average age at diagnosis for ADPKD has been previously quoted at 31.4 years 
(Bajwa et al., 2004). ADPKD is a genetically heterogeneous disorder; median age 
at death or onset of end stage renal failure (ESRF) is 53.0 years in individuals 
with a PKD1 mutation (responsible for approximately 85% of cases)  and 69.1 
years in those with PKD2 (responsible for approximately 15% of 
cases)(Hateboer et al., 1999).  However, there is variation in age of onset of end 
stage renal failure; previous estimates suggest that 2% of subjects affected by 
ADPKD develop ESRF by the age of 40; 23% by the age of 50, and 48% by the age 
of 73 (Churchill et al., 1984). As patients with ADPKD are often diagnosed in 
their third or fourth decade of life, this may impact on their family planning 
attitudes. 
 
Offspring of an affected parent have a 50% risk of inheriting ADPKD. Prenatal 
diagnosis usually involves taking a sample of placenta or amniotic fluid (typically  
in the late first trimester or early second trimester), for DNA analysis. Parents can 
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then be offered the option of terminating an affected pregnancy. In practice, 
prenatal diagnosis is rarely performed in ADPKD, and a previous survey of 
patients with ADPKD suggested that only 4-8% would terminate a pregnancy for 
ADPKD (Hodgkinson et al., 1990). Since then, preimplantation genetic diagnosis 
(PGD) has become available as an alternative to prenatal diagnosis (Sermon et al., 
2004; ESHERE PGD Consortium Steering Committee, 2002). However, although 
attitudes to prenatal diagnosis have been studied in the ADPKD population 
(Sujansky et al., 1990) we are not aware of any literature regarding patient 
attitudes to PGD in this setting. In PGD one or two cells from an embryo, made by 
in vitro fertilization, can be tested for a genetic abnormality and only embryos 
that do not carry the genetic abnormality are then implanted into the uterus. This 
enables parents with a genetic disease to have an unaffected child without 
needing to consider whether they would terminate an affected pregnancy. 
Although PGD is licensed in the UK by the Human Fertilisation and Embryology 
Authority for ADPKD (Human Ferilisation and Embryology Authority, 2015) and 
has been utilized for ADPKD previously (De Rycke et al., 2005), it is not available 
widely on the UK National Health Service, and the cost for treatment is 
approximately £6000 to £9000 per treatment cycle (Genetic Alliance UK, 2015). 
Importantly, it is unclear whether this approach is widely considered acceptable 
to patients. 
 
The scope of this study was to investigate attitudes of patients affected by ADPKD 
to determine whether there might be demand for PGD to be offered more widely 
to this population. This study aimed to compare interest for prenatal diagnosis 
and PGD in ADPKD patients with CKD (not requiring renal replacement therapy 
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(RRT)) and with ESRF . It has been demonstrated previously that disease severity 
in patients with hereditary cancer syndromes affected perceptions of the 
acceptability of PGD (Rich et al., 2014). ADPKD patients with ESRF receiving RRT 
have greater disease severity, are likely to have a poorer quality of life, and will 
probably have experienced a greater number of medical interventions. We 
hypothesized that this would translate into a greater acceptability towards PGD 
in the ESRF group. 
 
This study also evaluated attitudes towards termination of pregnancy in the 
ADPKD population and the influence of ADPKD on current and future family 
planning. . 
 
Materials and methods 
 
Study design and setting 
 
Ethical approval for data collection was obtained and authorised by South 
Yorkshire Research Ethics Committee (REC reference 14/YH/006, IRAS project 
ID 145961). 
 
This was a prospective study with patients recruited from two separate 
nephrology units in the UK: Royal Free London NHS Foundation Trust and East 
and North Hertfordshire NHS Trust. The study recruited two distinct groups of 
patients diagnosed with ADPKD:  
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1) 58 consecutive patients with ADPKD and CKD stages 1-4 (i.e. eGFR 
>15ml/min and not receiving RRT were recruited from a renal genetics clinic at 
the Royal Free Hospital looking after patients not receiving RRT  
2) 38 consecutive patients  with end-stage renal failure (ESRF) treated with 
either dialysis or transplantation, who were recruited from  dialysis units and 
the inpatient ward setting at East and North Hertfordshire NHS Trust. No 
patients with CKD stage 5 (eGFR <15ml/min) not receiving renal-replacement 
therapy were included. 
 
Inclusion and exclusion criteria 
 
Although the two study groups were recruited at different sites, inclusion and 
exclusion criteria were otherwise identical. All patients ≥18 years with a 
diagnosis of ADPKD were considered eligible. Additionally, patients included 
were required to have CKD stage 1-4 (Royal Free Hospital (RFH) cohort) or end-
stage renal failure treated with either dialysis or transplantation (East and North 
Hertfordshire NHS Trust (ENHT) Cohort). There were no exclusion criteria other 
than the language requirements sufficient to understand the information and 
consent sheets provided. All patients who were approached participated in the 
study.  
Study procedure 
 
A doctor approached patients for inclusion in the study face-to-face either in 
clinics, on an inpatient hospital ward or in their dialysis unit. After consenting to 
participate, an information sheet on PGD was provided whose content had been 
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agreed between a local clinical genetics department and the specialist ADPKD 
clinic. This was developed from a patient information sheet in clinical use; the 
University College London Centre for Reproductive and Genetic Health’s Patient 
Information Leaflet. The Research Ethics Committee also reviewed the 
information sheet content.  
 
The items in the questionnaire were based on a previous study (Menon et al., 
2007) that explored the views of BRCA carriers to PGD. Items relating to 
views on having children, prenatal diagnosis, termination of pregnancy and 
PGD were adapted to reflect the disease of interest, ADPKD. Additional items 
were included in the questionnaire relating to the patients' experience of 
ADPKD e.g. age at diagnosis, circumstances leading to diagnosis, family 
history, genetic testing; these were developed from clinical experience. 
Members of the research team with expertise in both genetics and ADPKD 
reviewed the questionnaire.  Please refer to the supplementary material for a 
copy of the questionnaire and patient information sheet.  
 
Data analysis 
 
Basic demographic and questionnaire data in the two study groups were 
reported descriptively and compared using Student’s T and chi-squared tests as 
appropriate. To determine potential factors influencing response to questions 
we compared age, gender, marital status, family history of ADPKD-related events 
and group (CKD or ESRF) between questionnaire response groups (yes, no or 
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unsure) using ANOVA, Chi-squared or T-tests as appropriate. In these analyses, 
family history of ADPKD-related events was considered a binary variable, which 
was 1 if any family member had required dialysis, transplant or suffered 
subarachnoid haemorrhage. Statistical analysis was performed using IBM SPSS 
version 22. 
 
Results 
 
Population demographics 
 
Overall, 96 patients with diagnosed ADPKD were included, comprising 58 with 
CKD stages 1-4 (RFH cohort) and 38 with ESRF (ENHT cohort). All patients who  
were approached consented to participation in the study. 
Of the ESRF group, 33 were receiving haemodialysis, 1 peritoneal dialysis and 4 
had a functioning renal transplant.  Demographic data relating to gender 
differences, presence of ESRF and marital status by age group are  detailed in 
Table 1. Median age of diagnosis of ADPKD was 30 years in the CKD group and 
42 years in the ESRF group. 
 
Diagnosis of ADPKD, family history and exposure of patients to ADPKD-related 
complications 
 
ADPKD-related events (defined as ESRF requiring RRT or subarachnoid 
haemorrhage) in family members are detailed in Table 2. Table 3 illustrates 
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proportions of participants with a family history of ADPKD and how the 
diagnosis of ADPKD was established in this cohort.   
 
Access to genetic counseling 
 
 A genetic counselor had seen 13% patients (17% in the CKD group compared to 
5% in the ESRF group (n=2)) and 9% (n=9) had undergone genetic testing to 
confirm the diagnosis of ADPKD (see table 3). 
Attitudes to family planning and termination of pregnancy 
 
Family planning attitudes are detailed in Figure 1. Participants were able to 
answer yes to more than one question relating to family planning attitudes, 
hence percentages in this figure add up to more than 100%.  
 
In the CKD group 55% had children, compared to 74% in the ESRF group. In the 
CKD group, 17% had plans for children in the future, compared to 0% in the 
ESRF group, likely explained by the greater age of individuals in the ESRF group.  
 
Examination of attitudes amongst the subgroup of patients (all with CKD) who 
have plans for children in the future (median age 27 years, range 20-38) showed 
that 80% of this cohort are worried about their children having ADPKD.  
 
Regarding attitudes to termination of pregnancy, 45% in the CKD group and 26% 
in the ESRF group considered it acceptable to terminate an apparently normal 
pregnancy if the woman decided she did not want to be pregnant (p = 0.09). In  
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the CKD group 57% participants and in the ESRF group 50% participants 
thought it acceptable to terminate a pregnancy if the child has a serious genetic 
abnormality, such as Trisomy 21 or cystic fibrosis. The majority of patients in 
both the CKD group (59%) and ESRF (65%) would not consider termination of 
pregnancy or prenatal diagnosis for ADPKD; 17% ADPKD patients with CKD and 
18% ADPKD patients with ESRF would consider prenatal diagnosis or 
termination of pregnancy for ADPKD (See figure 2). There were no significant 
differences in age (p= 0.68), gender (p=0.38), marital status (p=0.35), previous 
family experience of ADPKD-complications (p=0.12) or group (CKD or ESRF) (p= 
0.67) between patient response categories of acceptability of prenatal diagnosis 
and termination of pregnancy. 
 
Regarding attitudes of patients who still have plans for children in the future, 
70% thought it acceptable to terminate a pregnancy if the couple or woman 
decides she does not want to be pregnant in an apparently normal pregnancy, or 
if the child has a serious genetic abnormality, such as Trisomy 21 or cystic 
fibrosis.  Termination of pregnancy or prenatal diagnosis for ADPKD would not 
be considered by 60% of participants.  
 
 
Attitudes of patients to PGD and its funding source 
 
In the CKD group, 50% of participants  reported that they would either opt for or 
consider PGD compared to 63% of the ESRF group. There were no significant 
differences in age (p= 0.54), gender (p=0.33), marital status (p=0.76), previous 
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family experience of ADPKD-complications (p=0.21)  or group (CKD or ESRF) (p= 
0.33) between patient response categories of acceptability of PGD. In the 
subgroup of patients who had plans for children in the future, 40% (n =4) stated 
they would opt for PGD if the UK National Health Service funded it.  
 
Additionally, 69% of the CKD group and 68% of the ESRF group thought that 
PGD should be offered to other people with ADPKD, even if they would not 
consider it for themselves (See figure 3). In comparison, 19% of the CKD group 
(mean age 50) and 2.6% (n=1) of the ESRF group (mean age 60) believed that 
PGD should not be offered (p=0.049). The  cost of undertaking PGD if self-funded 
was cited as the most common factor  (27% all patients) that made participants 
decide against PGD. The inconvenience of having to go through in-vitro 
fertilization (IVF) being mentioned next most frequently (8%). 
 
Comments made by patients on topic of PGD 
 
There was an opportunity for patients to leave comments at the end of the 
questionnaire. Comments reflected the varying attitudes and experiences to 
ADPKD, prenatal diagnosis and PGD including: ‘Having kidney disease that is 
inherited makes it really stressful to decide about having children…PGD should 
be available as a free option’; ‘I wouldn’t want my children to go through what I 
have gone through’; ‘I would certainly take up PGD as any child I might have…has 
a high chance of having ADPKD too. Definitely should be offered’; ‘I have had a 
full and complete life and to a certain extent continue to do so…my middle child 
has polycystic kidneys... She is now 34, with a child of 4…Would I have done 
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anything different - including terminating her when I found out she had 
polycystic kidneys - absolutely not!’   
 
Discussion 
 
Attitudes towards prenatal diagnosis and PGD in CKD and ESRF groups 
There were no statistically significant differences between the CKD and ESRF 
groups in attitudes towards prenatal diagnosis and termination of pregnancy, 
with  61% of all patients not regarding ADPKD as justifying termination and less 
than 20% reporting that they would consider this themselves. In contrast, the 
majority of patients thought that termination of pregnancy was acceptable for 
Trisomy 21 or cystic fibrosis.  
In contrast, PGD appeared to have greater acceptability amongst both the CKD 
and ESRF groups than prenatal diagnosis or termination of pregnancy. There 
was no significant difference in attitudes between CKD and ESRF groups, which 
went against the hypothesis that there would be a greater acceptability within 
the ESRF group because of greater disease severity, poor quality of life and 
increased exposure to medical interventions. Age, gender, marital status, 
previous family experience of ADPKD-complications and group (CKD and ESRF) 
were not significant factors in the response of patients to PGD acceptability. 
Interestingly, a greater proportion of patients with CKD compared to those with 
ESRF believed that PGD should not be offered to patients with ADPKD. Mean age 
and relationship status within this subgroup was similar to the overall cohort 
thus these factors are unlikely to explain the differences found. Whether this 
divergence in views reflects differences in general life experience between the 
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groups, or results from direct experience of undergoing RRT in the ESRF group is 
unknown. Experience of significant ADPKD related events in family members 
were similar in both the CKD and ESRF groups. It may be that certain 
participants, irrespective of age and stage of family planning, do not feel that 
their disease is serious enough to warrant invasive testing such as PGD and that 
PGD would create a delay in having a child. The fact that ADPKD is an adult onset 
condition may also play a role. Previous studies that investigated attitudes 
towards family planning and theoretical intentions towards prenatal diagnosis 
and PGD amongst patients known to carry the BRCA1/2 mutation have identified 
that PGD would be pursued by just under a third of patients, with half stating 
that they would opt for prenatal diagnosis (Julian-Reynier et al., 2012).  
 
It should also be noted that exposure to genetic services and investigations, in 
the form of either genetic counselling or genetic diagnosis of ADPKD, was low in 
our cohort. Discussions between clinicians and patients at diagnosis regarding 
genetic counselling and genetic testing options should be encouraged in order to 
help inform family planning decision-making and potentially increase access to 
these services. 
 
The impact of severe ADPKD complications in family members did not 
significantly influence attitudes towards PGD. Equally, the impact of still having 
plans for children in the future did not significantly alter attitudes towards PGD.  
Thus it may be that additional personal factors, such as religious and moral 
views, play a role in deciding whether to pursue PGD prior to having a family.  
Recent advances in management of ADPKD 
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Recent advances in genetic testing with cheaper, automated high-throughput 
tests (Rossetti et al., 2012) may mean that genetic testing becomes more 
available, thus patients with the worst outlook as a result of a truncating 
mutation in PKD1 (Hateboer et al., 1999; Cornec-Le Gall et al., 2013) would be 
more aware of their prognosis and more likely to be referred for genetic 
counseling or consider PGD.  
 
In addition to the recent developments regarding prognostication, there have 
been encouraging advances in the treatment of ADPKD using the vasopressin 
(V2) receptor antagonist tolvaptan. Tolvaptan has been shown to reduce the rate 
of increase of total kidney volume and slow decline in estimated glomerular 
filtration rate (Torres et al., 2012). The impact of such disease modifying agents 
may reduce demand for PGD as patients may die naturally of other causes before 
they develop ESRF. Conversely, these new therapeutic agents may mean that 
more young patients with a family history of ADPKD undergo genetic testing in 
order to secure a diagnosis that may not be radiologically obvious prior to 
commencing treatment. As a result, an increasing number of ADPKD patients 
may have a confirmed genetic diagnosis when planning their family and may be 
more aware of the reproductive options available to them. 
 
Potential obstacles to performing PGD in ADPKD 
However, it is also important to also consider some of the complications and 
difficulties that occur in performing PGD in ADPKD. There is no certainty of IVF 
being successful and there is an increased risk of multiple pregnancy and ovarian 
hyperstimulation syndrome (Khalid et al., 2015). PGD is also technically difficult 
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and there is a risk of sample contamination and allele drop-out (where one of the 
two alleles fails to amplify, giving rise to a false negative result in autosomal 
dominant diseases).  
 
In addition, prospective parents would require a genetic diagnosis to identify 
their own mutation prior to commencing PGD. In ADPKD 5% of mutations arise 
spontaneously (Grantham, 2008) and as a result these patients  cannot undergo 
linkage analysis.  Furthermore, 333 truncating PKD1 (including missense 
mutations and silent polymorphisms) and 95 truncating PKD2 mutations have 
been described in ADPKD (Torres and Harris, 2009). Screening individuals with 
ADPKD detects mutations in up to 91% of cases. However only approximately 
65% of patients have definite mutations with approximately 26% having 
variants of uncertain significance that require further evaluation (Harris and 
Rossetti, 2010). 
 
Study limitations and overall conclusion 
The limitations of this study include the fact that the results are patients’ 
speculative intentions. Not all patients were given time to ask questions 
regarding the information about prenatal diagnosis and PGD. Participants 
completed the questionnaire unsupervised and may have benefited from a 
researcher presence to clarify certain points. However, we felt the presence of a 
researcher may unduly bias responses to questions. Consequently, participants 
may not have correctly understood some of the information about prenatal 
diagnosis and PGD. In particular, the potential complications of prenatal 
diagnosis and PGD were not explained in detail. Information about patient’s 
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theoretical plans is interesting however, as it gives an idea as to how attitudes in 
ADPKD patients to prenatal diagnosis and PGD may change with the evolution of 
disease modifying agents. 
 
In addition, the CKD group and ESRF group were obtained from two separate 
populations. This could have introduced factors that were not evaluated that 
may have influenced attitudes towards prenatal diagnosis and PGD (and hence 
affected the results) including religion, personal values, social status and income. 
 
If PGD for ADPKD were to become more widely funded by  the UK National 
Health Service, there could be uptake as high as 69% among patients with 
ADPKD based on our survey results . It is not known how advances in methods to 
stratify prognosis or the availability of treatments that alter the natural history 
of this disease, such as tolvaptan, will affect these attitudes.  
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